Radar · Infectious Diseases in Maryland
Best Infectious Diseases Companies in Maryland, United States
The 60 best Infectious Diseases companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novavax.
By Riya SenguptaFinancials
60companies tracked
$4.7Bdisclosed funding
0unicorns
43have raised
FLIAR INTELLIGENCE · INFECTIOUS DISEASES × MARYLAND
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
59%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2014median founding year
161kcombined LinkedIn audience
87%of audience held by top 3
1companies hiring publicly (12 mo)
Ranked: Best Infectious Diseases companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Novavax Developer of novel vaccines for the treatment of infectious diseases 83Product top 14%Patents top 17%Funding top 22%Innovation top 23% All 13 signals ▾Producttop 14% Patentstop 17% Fundingtop 22% Innovationtop 23% Partnerstop 26% Markettop 28% Moattop 29% Fin. healthtop 32% Globaltop 35% Growthtop 37% Newstop 40% Techtop 41% Talentbottom 48% Product: 4 distinct product lines · Company stage: Public Patents: 599 patents matched (strict assignee match) · 193 filings since 2022 vs 135 in 2017-21 rank vs industry peers · Fliar Intelligence Index 83/100 | $2.7B | 34 mo ago | 184 | John Jacobs President | Public | 599 patents Patents concentrated in chemistry & materials | 2 launchs · 2 partnerships |
| 2 | Emergent BioSolutions Developer of vaccines primarily for virus infections | $491M | 46 mo ago | 1,600 1,600 → 1,366 (-15%) | — | Public | 29 patents Vaccines and therapeutic antibodies targeting high‑risk biothreat pathogens | 1 award |
| 3 | Precigen Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious… | $234M | 66 mo ago | 25 | Thomas Reed Founder | Public | 262 patents Gene and cell therapy platforms, viral vector vaccines, and electroporation delivery technologies. | — |
| 4 | Barinthus Biotherapeutics Developer of T-cell immunotherapeutics to treat multiple diseases | $210M | 30 mo ago | — | Adrian Hill Co-Founder | Public | 33 patents Peptide vaccine nanocarriers for cancer immunotherapy and targeted drug delivery | — |
| 5 | Sanaria Developer of whole-parasite malaria vaccines for infectious diseases 48Funding top 23%Patents top 33%Moat top 41%Innovation top 46% All 8 signals ▾Fundingtop 23% Patentstop 33% Moattop 41% Innovationtop 46% Growthtop 47% Marketbottom 44% Techbottom 44% Globalbottom 37% Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $188M | 10 mo ago | 77 | — | Funding Raised | 134 patents Malaria vaccine production, sporozoite cryopreservation, and vector storage technologies | — |
| 6 | adaptive phage therapeutics Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic… | $108M | 37 mo ago | 66 | — | Acquired | — | — |
| 7 | VIRxSYS Developing genetic therapies for HIV and cancer | $106M | 174 mo ago | — | Riku Heikki Rautsola Ex President and CEO | Deadpooled | 105 patents Therapeutic apoptosis-inducing agents, lentiviral gene‑therapy vectors, and RNA trans‑splicing platforms | — |
| 8 | OpGen Developer of diagnostics and bioinformatics platforms for providers | $78M | 64 mo ago | 100 | — | Public | 111 patents Antimicrobial resistance profiling and rapid antibiotic susceptibility testing technologies. | — |
| 9 | Genvec Developer of gene-based vaccines for hearing loss and balance disorders | $62M | 159 mo ago | 16 | — | Acqui-Hired | 331 patents Adenoviral vector platforms for veterinary and human vaccines and gene therapy | — |
| 10 | Iomai Corporation Online dissertation writing help, advice, and resources for graduate students | $54M | 282 mo ago | 110 | Gerd Zettlmeissl CEO | Acquired | 14 patents Patents concentrated in health & consumer products | — |
| 11 | American Gene Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases 55Funding top 24%Patents top 31%Moat top 35%Talent top 35% All 11 signals ▾Fundingtop 24% Patentstop 31% Moattop 35% Talenttop 35% Innovationtop 37% Growthtop 40% Producttop 40% Techtop 46% Marketbottom 36% Globalbottom 36% Newsbottom 22% Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $53M | 8 mo ago | 31 | Jeff Galvin Chief Executive Officer | Series B | 228 patents Non-integrating viral vectors for gene delivery and HIV immunotherapy, plus gamma‑delta T‑cell activation | — |
| 12 | PharmAthene Developing anthrax vaccine designed to protect against inhalational anthrax. | $50M | 187 mo ago | 15 | Vipin Garg CEO | Public | 29 patents Patents concentrated in health & consumer products | — |
| 13 | Maxim Biomedical Diagnostic testing solutions improving public health and healthcare worldwide | $50M | 30 mo ago | 22 22 → 15 (-32%) | Joe Ma Founder & President | Funding Raised | — | — |
| 14 | Abvacc Developer of vaccines and therapeutics to treat infectious diseases 35Funding top 30%Moat top 38%Patents top 43%Innovation top 50% All 7 signals ▾Fundingtop 30% Moattop 38% Patentstop 43% Innovationtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 31% Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $46M | 13 mo ago | — | M Aman Founder | Funding Raised | 6 patents Vaccines targeting bacterial toxins and cell‑wall domains for immunotherapy | — |
| 15 | Akonni Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification | $40M | 57 mo ago | 12 12 → 15 (+25%) | — | Series C | — | — |
| 16 | VLP Therapeutics Developer of therapeutic vaccines for the treatment of cancer, infectious and CNS disease | $37M | 35 mo ago | 15 | Wataru Akahata Co-Founder & CEO | Series A | — | — |
| 17 | Synthetic Biologics Developing oncolytic virus therapies to overcome solid tumor barriers | $31M | 47 mo ago | 21 | — | Late Stage | 208 patents Microbiome-protective enzyme therapeutics and engineered biologics for infection and metabolic control | — |
| 18 | Scanogen Provider of single-molecule biosensors for cancer diagnostics 29Talent top 28%Moat top 32%Funding top 33%Patents top 35% All 9 signals ▾Talenttop 28% Moattop 32% Fundingtop 33% Patentstop 35% Innovationtop 42% Productbottom 44% Globalbottom 35% Techbottom 28% Marketbottom 21% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $29M | 11 mo ago | 7 | — | Funding Raised | 26 patents Biosensor and imaging technologies for rapid medical analyte detection and diagnostics | — |
| 19 | Profectus BioSciences Using proprietary discovery engine to develop vaccines against viral infectious diseases and their associated… | $19M | 122 mo ago | 3 | — | Deadpooled | 41 patents Engineering recombinant viral vectors for gene therapy and vaccine delivery | — |
| 20 | Alphyn Biologics Developer of therapeutics for severe and common skin diseases 27Patents top 28%Moat top 32%Innovation top 33%Funding top 37% All 7 signals ▾Patentstop 28% Moattop 32% Innovationtop 33% Fundingtop 37% Techbottom 43% Globalbottom 40% Marketbottom 16% Patents: 30 patents matched (strict assignee match) · 21 filings since 2022 vs 9 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 30 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $13M | 6 mo ago | 3 | — | Series B | 25 patents Topical antibacterial skin treatments using croton lechleri-derived pharmaceutical compositions | — |
| 21 | mRNA Developer of therapeutics for the treatment of cancer, rare diseases, and others | $12M | 51 mo ago | 9 | Dong Shen CEO | Series A | — | — |
| 22 | Functional Genetics Small molecule and antibody therapeutics for viral diseases | $11M | 192 mo ago | 50 | — | Deadpooled | 90 patents Viral infection inhibition and gene‑perturbation platforms for antibody/therapeutic development | — |
| 23 | Biological Mimetics Innovating biomedical solutions to combat global infections and improve public health | $11M | 25 mo ago | — | Peter Nara CEO | Funding Raised | 39 patents Inactivated microbial vaccine formulations and multiplex pathogen detection device technologies. | — |
| 24 | PathoVax Prophylactic vaccine against all 15 oncogenic human papillomavirus. | $10M | 74 mo ago | 3 | Travis Stiles Co-Founder and Interim CEO | Deadpooled | 11 patents Virus-like particle platforms for antigen-specific vaccine and immune response redirection | — |
| 25 | BioFactura Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs | $8M | 86 mo ago | 33 | Darryl Sampey President and CEO | Series B | 46 patents Antiviral therapeutics and vaccine compositions for orthopoxvirus infection treatment | — |
| 26 | Zero Point Five Therapeutics Developer of therapeutics for infectious diseases | $7M | 15 mo ago | — | Joseph Amprey Co-Founder & CEO | Series A | — | — |
| 27 | AccelevirDx Developer of diagnostic assays for HIV | $7M | 15 mo ago | 8 | Albine Martin Co-Founder/Investor | Funding Raised | — | — |
| 28 | Integrated BioTherapeutics Vaccines and Antibodies for bacterial & viral infections | $5M | 38 mo ago | 43 | Javad Aman CEO | Series A | 82 patents Therapeutic antibodies and toxin-derived peptides targeting viral and bacterial infections | 1 job opening · 1 launch |
| 29 | Hememics Biotechnologies Developer of techology platform for biopreservation | $5M | 37 mo ago | 13 | Stephen Bruttig Chairman | Seed | 36 patents Rapid multiplex point‑of‑care biosensors employing carbon‑nanotube nanomaterials | — |
| 30 | Pearl Diagnostics Foundation focused on detection and prevention of fungal infections 13Funding top 35%Talent bottom 49%Global bottom 32%Market bottom 20% All 4 signals ▾Fundingtop 35% Talentbottom 49% Globalbottom 32% Marketbottom 20% Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 13/100 | $4M | 3 mo ago | 6 | Kieren Marr Founder & CEO | Series B | — | — |
| 31 | Astek Diagnostics Manufacturer of blood test diagnostic device | $3M | 27 mo ago | 8 | — | Seed | — | — |
| 32 | Primetime Life Sciences Developer of translational medicine | $3M | 82 mo ago | — | Janak Padia President & CEO | Funding Raised | — | — |
| 33 | DFH Pharma Developer of pharmaceutical products, focusing on drug development and medical trends | $2M | 9 mo ago | — | Carl Wild Founder & CEO | Funding Raised | — | — |
| 34 | CCL Biomedical Operator of antimicrobial compounds for combatting health issues and reducing infections | $1M | 207 mo ago | 3 | — | Funding Raised | — | — |
| 35 | Medigen Developing safe, effective vaccines against emerging diseases for lifelong immunity | $992K | 178 mo ago | 36 | — | Funding Raised | 60 patents VLP-based vaccine platforms using bovine immunodeficiency virus gag for influenza and alphavirus immunization | — |
| 36 | HBVtech Developer of therapeutics for hepatitis B infection through a single injection | $839K | 10 mo ago | 2 | — | Funding Raised | 11 patents Therapeutics targeting hepatitis B virus cccDNA elimination and HBsAg reduction | — |
| 37 | NeuImmune Developer of vaccine and therapeutics for infectious diseases | $574K | 35 mo ago | — | Nathan Lewis Co-Founder | Funding Raised | — | — |
| 38 | Pataigin Assays to identify pathogens using mass spectrometry | $555K | 35 mo ago | — | Erik Nilsson CEO | Funding Raised | 7 patents Biotech sample processing and growth assay analytics for nucleic acid diagnostics. | — |
| 39 | Drizzle Developer of diagnostic kits for the detections & identification of Tuberculosis | $500K | 19 mo ago | 3 | — | Seed | — | 1 partnership |
| 40 | 3i Diagnostics Provider of diagnostics solution for infectious diseases | $481K | 72 mo ago | 5 | Rajesh Krishnamurthy Founder | Funding Raised | 94 patents Cooperative primer technologies for nucleic acid amplification, variant genotyping, and pathogen detection | — |
| 41 | HepC Developer of antiviral biologic products | $400K | — | — | Thomas Bakacs CEO | Funding Raised | — | — |
| 42 | Fyodor Biotechnologies Developer of rapid diagnostic kits for infectious disease | $345K | 107 mo ago | 1 | Eddy Agbo CEO & Chairman | Seed | — | — |
| 43 | Tetracore Biotechnology company providing detection tools for clinical, animal health, and biothreat testing | $249K | 137 mo ago | 120 | William Nelson President/CEO | Funding Raised | 53 patents Integrated point‑of‑care sample preparation and nucleic‑acid amplification devices | — |
Top 12 Infectious Diseases companies in Maryland
#1
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees$187.8Mraised▾
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees
Developer of whole-parasite malaria vaccines for infectious diseases. The company is developing protective vaccines against malaria and plasmodium falciparum infection in humans.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 23%Patents
top 33%Moat
top 41%Innovation
top 46%Growth
top 47%Market
bottom 44%Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 1/10 · IP moat: 134 patents
Funding rounds
- Sep 2025Grant (prize money)$2M
- Sep 2025Grant (prize money)$5.9M
- Jul 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$988.8K
Investors
NIAID, Gates, HHS
Tech stack
Animate.CssBootstrapContact Form 7Core-JsFont AwesomeGoogle Analytics
#2
Series B · Rockville, Maryland · founded 2008 · 31 employees$52.8Mraised▾
Series B · Rockville, Maryland · founded 2008 · 31 employees
Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases. The company has developed drugs using its delivery platform. The product pipeline includes a liver cancer therapeutic lentivirus and an AIDS therapeutic lentivirus, as well as Parkinson’s disease therapeutic lentivirus, and a familial dysautonomia therapeutic lentivirus.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 24%Patents
top 31%Moat
top 35%Talent
top 35%Innovation
top 37%Growth
top 40%Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) · Last round Series B (Nov 2025)
Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 228 patents · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series B$310K
- Apr 2022Series B$50M
- Nov 2015Series A$1.2M
- Sep 2015Grant (prize money)$232.2K
Founders & team
Investors
NIH, Ride wave ventures, HHS, Gaingels, Alumni Ventures
Tech stack
AddtoanyAddtoany Share ButtonsAmazon SesAmazon Web ServicesBeaver BuilderCdnjs
#3
Series B · Annapolis, Maryland · founded 2019 · 3 employees$12.6Mraised▾
Series B · Annapolis, Maryland · founded 2019 · 3 employees
Developer of therapeutics for severe and common skin diseases. The lead candidate of the company AB-101 is the topical drug to treat skin infections caused by MRSA bacteria, Pseudomonas, and other multi-drug resistant organisms (MDOs). The substance AB-101 is generated by an available tropical plant as its own defense against bacteria.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Patents
top 28%Moat
top 32%Innovation
top 33%Funding
top 37%Tech
bottom 43%Global
bottom 40%Patents: 30 patents matched (strict assignee match) · 21 filings since 2022 vs 9 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 4/10 · IP moat: 30 patents
Innovation: 30 patents (top 42% of patent-holders) · 21 filings since 2022 vs 9 in 2017-21
Audience (LinkedIn): 908 LinkedIn followers
Funding rounds
- Dec 2025Series B$25M
- Mar 2024Series B$5.2M
- May 2023Series A$1.2M
- Sep 2022Series A$3.3M
Investors
Queen City Angels, Angel Physicians Fund, Serial Stage Venture Partners
Tech stack
Animate.CssCloudflareCloudflare Bot ManagementContact Form 7Core-JsGodaddy
#4
Series B · Baltimore, Maryland · founded 2014 · 6 employees$3.5Mraised▾
Series B · Baltimore, Maryland · founded 2014 · 6 employees
Foundation focused on detection and prevention of fungal infections
Fliar Intelligence Index™ 13how this company ranks against its industry peers
Funding
top 35%Talent
bottom 49%Global
bottom 32%Market
bottom 20%Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) · Last round Series B (Mar 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Single-market focus (United States)
Funding rounds
- Mar 2026Series B$11.2M
- Jun 2022Series A$3.5M
- Mar 2021Grant (prize money)$976.6K
- Jul 2015Grant (prize money)$175K
Founders & team
Investors
HHS, TEDCO
#5
Funding Raised · Baltimore, Maryland · founded 2011 · 7 employees$28.6Mraised▾
Funding Raised · Baltimore, Maryland · founded 2011 · 7 employees
Provider of single-molecule biosensors for cancer diagnostics. The company's semiconductor-based technology uses DNA supercoiling to convert nucleic acid hybridization into a mechanical signal for rapid diagnostics. The first application is for the detection of drug-resistant microbes, specifically tuberculosis.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Talent
top 28%Moat
top 32%Funding
top 33%Patents
top 35%Innovation
top 42%Product
bottom 44%Talent: Analyst team rating 4/5
Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents
Funding: Raised $28.6M across 15 rounds · 15 rounds over 13 yrs (1.2/yr) · Last round Grant (prize money) (Jul 2025)
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Jul 2025Grant (prize money)$3M
- Jun 2025Grant (prize money)$5M
- May 2025Grant (prize money)$3.3M
- Aug 2023Grant (prize money)$2M
Investors
HHS
Tech stack
BootstrapApache Http ServerCloudflareJqueryGoogle AnalyticsFont Awesome
#6
Funding Raised · Rockville, Maryland · founded 2023$45.5Mraised▾
Funding Raised · Rockville, Maryland · founded 2023
Developer of vaccines and therapeutics to treat infectious diseases. The company's pipeline includes product candidates for the prevention and treatment of bacterial and viral infections. It has a bacterial program that primarily focuses on staphylococcal infections by targeting a variety of virulence factors such as toxins and critical enzymes produced by S. aureus. The company has also developed a large collection of potently neutralizing fully human and macaque-human chimeric antibody therapeutics and vaccines for filoviruses and the Nipah virus.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 30%Moat
top 38%Patents
top 43%Innovation
top 50%Talent
bottom 49%Market
bottom 37%Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) · Last round Grant (prize money) (May 2025)
Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents
Patents: 6 patents matched (strict assignee match) · 4 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Funding rounds
- May 2025Grant (prize money)$1.3M
- May 2025Grant (prize money)$1.3M
- Apr 2025Grant (prize money)$6.6M
- Feb 2025Grant (prize money)$3M
Founders & team
Investors
HHS
#7
Public · Gaithersburg, Maryland · founded 1987 · 184 employees$2.7Braised▾
Public · Gaithersburg, Maryland · founded 1987 · 184 employees
Developer of novel vaccines for the treatment of infectious diseases. Its pipeline includes a vaccine for respiratory syncytial virus infection, coronavirus, malaria, ebola, and seasonal quadrivalent vaccines for influenza. It uses recombinant nanoparticles and adjuvant technology.
Fliar Intelligence Index™ 83how this company ranks against its industry peers
Product
top 14%Patents
top 17%Funding
top 22%Innovation
top 23%Partners
top 26%Market
top 28%Product: 4 distinct product lines · Company stage: Public
Patents: 599 patents matched (strict assignee match) · 193 filings since 2022 vs 135 in 2017-21 · Latest publication 2026
Funding: Raised $2.7B across 15 rounds · 15 rounds over 21 yrs (0.7/yr) · Last round Post IPO (Sep 2023)
Audience (LinkedIn): 80k LinkedIn followers — 49.5% of this cohort's audience
Activity (LinkedIn): 2 product launches · 2 partnerships (incl. Matrix-M®) announced in 12 mo
Funding rounds
- Sep 2023Post IPO$84.5M
- Jul 2020Grant (prize money)$1.6B
- Jun 2020Post IPO$200M
- Jun 2020Grant (prize money)$60M
Founders & team
Investors
InnovationsKapital, SK bioscience, CEPI, Gates, NIH, PATH
Tech stack
Acquia Cloud PlatformAddtoanyAmazon Web ServicesAosApple Icloud MailBootstrap
#8
Funding Raised · Gaithersburg, Maryland · founded 2011$2.3Mraised▾
Funding Raised · Gaithersburg, Maryland · founded 2011
Developer of pharmaceutical products, focusing on drug development and medical trends. The company strives to improve patient health within the healthcare industry. Its team monitors medical advancements and technology. The company focuses on finding better methods in an evolving industry.
Funding rounds
- Sep 2025Grant (prize money)$986.9K
- Jul 2020Grant (prize money)$943.1K
- Sep 2018Grant (prize money)$171.5K
- Aug 2013Grant (prize money)$186.4K
Founders & team
Investors
HHS
#9
Funding Raised · Baltimore, Maryland · founded 2015 · 8 employees$6.5Mraised▾
Funding Raised · Baltimore, Maryland · founded 2015 · 8 employees
Developer of diagnostic assays for HIV. The assay detects ultra-rare analytes of HIV and other viral infections in the blood. The company uses ddPCR, qPCR, sequencing, and also culture-based methods to develop assays.
Funding rounds
- Apr 2025Grant (prize money)$755.3K
- Feb 2025Grant (prize money)$600K
- Jul 2021Grant (prize money)$600K
- Dec 2019Grant (prize money)$300K
Founders & team
Investors
HHS
Tech stack
Apache Http ServerCloudflare TurnstileCore-JsElementorFancyboxGoogle Analytics
#10
Series A · Baltimore, Maryland · founded 2018$7.2Mraised▾
Series A · Baltimore, Maryland · founded 2018
Developer of therapeutics for infectious diseases. It offers ZP5-9676 a single-dose therapy intended to treat soil-transmitted helminths, including Ascaris (roundworm), Trichuris (whipworm), Necator americanus and the uncommon Ancylostoma duodenale.
Funding rounds
- Apr 2025Series A$4.3M
- Jul 2023Series A$7.2M
Founders & team
#11
Public · Germantown, Maryland · founded 2016$209.7Mraised▾
Public · Germantown, Maryland · founded 2016
Developer of T-cell immunotherapeutics to treat multiple diseases. The company has proprietary platform technologies ChAdOx, MVA, SNAP-TI, and SNAP-CI to develop pipeline of product candidates across a diverse range of therapeutic areas including chronic infectious diseases, autoimmunity, and cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 11k LinkedIn followers — 6.5% of this cohort's audience
Activity: 3 partnerships (incl. Clywedog Therapeutics Inc) announced in 12 mo
Funding rounds
- Dec 2023Post IPO$34.8M
- Mar 2021Series B$168M
- Jan 2018Series A$27.3M
- May 2016Seed$14.4M
Founders & team
Investors
Sequoia Capital, Google Ventures, Oxford Science Enterprises, Neptune Ventures, Future Planet Capital, M&G
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#12
Funding Raised · Germantown, Maryland · founded 2013 · 2 employees$838.6Kraised▾
Funding Raised · Germantown, Maryland · founded 2013 · 2 employees
Developer of therapeutics for hepatitis B infection through a single injection. It utilizes an optimized AAV vector that carries human anti-HBs antibody genes to endogenously express human anti-HBs antibody and treats hepatitis B infection.
Funding rounds
- Aug 2025Grant (prize money)$258.8K
- May 2021Grant (prize money)$279.9K
- Mar 2021Grant (prize money)$300K
Investors
HHS
Funding & investor landscape
$4.7Btotal disclosed funding
43companies funded
340disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Jeff Galvin
Chief Executive Officer · American Gene
Kieren Marr
Founder & CEO · Pearl Diagnostics
M Aman
Founder · Abvacc
John Jacobs
President · Novavax
Stanley Erck
Advisor to the Board of Directors · Novavax
Carl Wild
Founder & CEO · DFH Pharma
Albine Martin
Co-Founder/Investor · AccelevirDx
Joseph Amprey
Co-Founder & CEO · Zero Point Five Therapeutics
Helen Pentikis
Co-Founder & CEO · Zero Point Five Therapeutics
Adrian Hill
Co-Founder · Barinthus Biotherapeutics
Sarah Gilbert
Co-Founder · Barinthus Biotherapeutics
Joe Ma
Founder & President · Maxim Biomedical
Prism market signals · United States · country-scoped Prism corpus, 1,265,774 docs
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
RESEARCH IN MARYLAND · Health & Bio
How research on Diagnostics in Maryland is moving
A read on the academic research around Diagnostics in Maryland — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 63 papers.
University of Maryland's institutions cautiously advance diagnostics research—spanning malaria, cancer genomics, and biosensors—with a mildly optimistic tone (0.29) balanced by notable concern.
63 papers · stance +0.29 · 12% breakthrough · 28% concern
top institutions
- University of Maryland, Baltimore52
- University of Maryland, College Park11
- University of Maryland, Baltimore County3
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center3
- University of Maryland Medical Center Midtown Campus2
leading researchers
Robert H. Christenson · Chai Shwai Prue · Sabeena Ahmed · Alessandro Russo · David J. Boegner · Diego de Miguel‐Pérez
prism intelligence · tone & topics
79% positive · 17% critical tone
HealthcareHealthPharmaceuticalsBiotechnologyClinical TrialsMedical Research
▲
Breakthroughs6 · 10%
▲ 0%→16% share
5 median citations67% since 2021mostly methods-led
Point-of-care diagnostics newly emerged as a breakthrough segment, capturing 16% field-share from zero.
rising sub-themes (early→recent)
- Point of care3
- Point-of-care testing2
- Biomarker2
- Wastewater1
- Software deployment1
Newly emergingPoint of care 0→3
Landmark A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations · 32 cites
◆
Advancements30 · 48%
▲ 36%→56% share
▲1.6× share momentum5 median citations47% since 2021mostly empirical
Liquid biopsy newly entered advancements with 4 papers as field-share rose from 36% to 56%.
rising sub-themes (early→recent)
- Malaria2→4
- Point of care2→3
Newly emergingLiquid biopsy 0→4
Landmark Exosomal HSP60: a potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment · 99 cites
▼
Concerns14 · 22%
▼ 23%→16% share
▼0.7× share momentum23 median citations29% since 2021mostly reviews
Point-of-care testing concerns are intensifying — rising to 6 papers even as concern field-share shrank from 23% to 16%.
rising sub-themes (early→recent)
- Point-of-care testing6
- Point of care5
- Intensive care medicine5
- Point (geometry)3
- Biomarker3
Landmark Stroke Biomarkers: Progress and Challenges for Diagnosis, Prognosis, Differentiation, and Treatment · 251 cites
Common questions
How many Infectious Diseases companies are there in Maryland, United States?
Radar tracks 60 indexable Infectious Diseases companies headquartered in Maryland, United States that meet our profile-completeness bar.
What is the total funding raised by Infectious Diseases companies in Maryland, United States?
The Infectious Diseases companies in Maryland, United States on this list have raised a combined $4.7B in disclosed equity funding across 43 funded companies.
Which is the highest-funded Infectious Diseases company in Maryland, United States?
Novavax is the highest-funded Infectious Diseases company in Maryland, United States, with $2.7B in disclosed equity funding.
How many Infectious Diseases companies in Maryland, United States are funded?
43 of the 60 Infectious Diseases companies in Maryland, United States on this list have disclosed at least one equity funding round.
How many Infectious Diseases unicorns are there in Maryland, United States?
None of the Infectious Diseases companies in Maryland, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Maryland, United States Infectious Diseases companies?
The most active investors in Maryland, United States Infectious Diseases companies on this list include HHS, Business Innovation Network, NIH, NIAID, National Science Foundation.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.